DP02 Expression of AMBRA1 and loricrin in the epidermis overlying benign cutaneous naevi, including blue and dysplastic naevi, is similar to that seen in normal skin, but expression may rarely be altered in melanoma in situ

Akhtar Husain,Penny Lovat,Grant Richardson,Thomas Ness,Claire Jones,Catherine Graham,Marie Labus,Philip Sloan
DOI: https://doi.org/10.1093/bjd/ljae090.224
IF: 11.113
2024-06-28
British Journal of Dermatology
Abstract:Abstract The epidermal expression of AMBRA1 and loricrin overlying primary melanomas has recently been validated as a prognostic biomarker able to identify genuinely low risk nonulcerated American Joint Committee on Cancer stage I/II tumours. We have previously shown that the loss of these biomarkers is due to secretion of transforming growth factor-β2 by the underlying tumour cells, and hypothesize that this mechanism is used by melanomas at risk of metastasis to facilitate premalignant dissemination. The aim of the present study was to evaluate the potential for the combined expression of AMBRA1 and loricrin to characterize a range of melanocytic naevi and melanoma in situ as benign or malignant. Formalin-fixed paraffin-embedded tissue sections were obtained derived from a representative selection of benign naevi and melanoma in situ from the cellular pathology archive of Newcastle upon Tyne Hospitals NHS Foundation Trust. These comprised 5 intradermal naevus, 16 dysplastic naevus (severe/moderate), 5 junctional naevus, 5 compound naevus, 6 common blue naevus, 5 cellular blue naevus, 2 combined naevus, 1 melanocytoma and 26 melanoma in situ. All sections were subjected to automated immunohistochemical analysis for AMBRA1 and loricrin expression. Staining patterns and expression were evaluated using consensus scoring by the study cellular pathologists (A.H., P.S.). All of the benign and dysplastic melanocytic naevi examined showed maintenance of both AMBRA1 and loricrin in the epidermis overlying the lesion, in line with their expression in normal skin. A maintained pattern was also seen in 24 of 26 cases of melanoma in situ, but two cases displayed focal losses of both AMBRA1 and loricrin. On review, both cases showed no evidence of melanoma in further levels and there was no clinical progression. The maintained pattern of AMBRA1 and loricrin was expected in the melanocytic naevi and is consistent with their benign nature. However, loss of expression of AMBRA1 and loricrin in two cases of melanoma in situ was unexpected, suggesting that some cases of melanoma in situ may contain melanocytes with malignant potential. Collectively these data warrant the further investigation of AMBRA1 and loricrin expression in a larger cohort to investigate their potential as biomarkers to distinguish between benign melanocytic lesions and those at risk of malignant progression. This study is funded by the Innovate UK Combined Investor Partnerships Award Round 11 (reference 10083008-1586) awarded to AMLo Biosciences.
dermatology
What problem does this paper attempt to address?